AI drug discovery enters physical validation: Insilico, Recursion, FutureHouse and Google DeepMind credited with new milestones
Peer-reviewed data for AI-generated peptides, enzymes and CRISPR variants, plus AI-designed compounds entering human trials, push in silico models into preclinical reality.
By Ryan Merket · Published
Primary source: Aligned News — AI Intelligence
Why it matters
Peer-reviewed wet-lab data and first-in-human entries for AI-designed molecules shift AI drug discovery from promise to practice, raising the bar for credibility, partnerships, and capital.
AI drug discovery crossed a line into physical validation this week: peer-reviewed preclinical results for AI-generated peptides, enzymes and CRISPR variants are out, and AI-designed compounds are entering human trials, according to Aligned News - AI Intelligence. The post credits Insilico Medicine, Recursion Pharmaceuticals, FutureHouse, and Google DeepMind with the week's milestones.